Analyst Price Targets — TYRA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 5, 2026 7:10 pm | Maury Raycroft | Jefferies | $42.00 | $25.71 | TheFly | Tyra Biosciences price target lowered to $42 from $44 at Jefferies |
| April 14, 2026 8:14 pm | Brad Canino | Guggenheim | $54.00 | $35.27 | TheFly | Tyra Biosciences initiated with a Buy at Guggenheim |
| February 17, 2026 11:12 am | Mitchell Kapoor | H.C. Wainwright | $45.00 | $27.99 | TheFly | Tyra Biosciences price target raised to $45 from $30 at H.C. Wainwright |
| February 13, 2026 2:03 pm | Robert Driscoll | Wedbush | $53.00 | $30.10 | TheFly | Tyra Biosciences price target raised to $53 from $37 at Wedbush |
| February 3, 2026 1:04 pm | — | Oppenheimer | $50.00 | $31.72 | TheFly | Tyra Biosciences price target raised to $50 from $36 at Oppenheimer |
| January 27, 2026 9:30 pm | — | Barclays | $59.00 | $31.40 | TheFly | Tyra Biosciences initiated with an Overweight at Barclays |
| January 23, 2026 11:59 am | — | Piper Sandler | $42.00 | $30.91 | TheFly | Tyra Biosciences price target raised to $42 from $33 at Piper Sandler |
| December 16, 2025 11:20 am | Robert Driscoll | Wedbush | $37.00 | $22.11 | TheFly | Wedbush raises price target on Tyra Biosciences, adds to Best Ideas List |
| September 10, 2025 11:03 am | Matthew Biegler | Oppenheimer | $36.00 | $12.18 | TheFly | Tyra Biosciences price target raised to $36 from $30 at Oppenheimer |
| November 11, 2024 12:23 pm | Mitchell Kapoor | H.C. Wainwright | $30.00 | $16.70 | StreetInsider | Tyra Biosciences (TYRA) PT Lowered to $30 at H.C. Wainwright |
Latest News for TYRA
Tyra Biosciences, Inc. (NASDAQ: TYRA - Get Free Report) has received a consensus rating of "Moderate Buy" from the fifteen ratings firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have given a buy rating and one has given
Algert Global LLC increased its stake in shares of Tyra Biosciences, Inc. (NASDAQ: TYRA) by 27.2% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 239,120 shares of the company's stock after buying an additional 51,110 shares during the period. Algert Global LLC owned
5AM Venture Management LLC bought a new position in Tyra Biosciences, Inc. (NASDAQ: TYRA) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 1,029,298 shares of the company's stock, valued at approximately $32,875,778,000. Tyra Biosciences makes up approximately 11.4%
TYRA's dabogratinib has an upcoming readout in September 2026 that I think could validate its FGFR3 profile. However, if they succeed with that trial, I believe it would also help TYRA's broader SNAP drug-design platform. In that sense, a strong, complete-response signal with a good safety profile could de-risk dabogratinib and improve TYRA's risk-reward profile as a whole.
- Initial Ph2 data from SURF302 expected in September 2026 (n>40 enrolled to date) - - Initial Ph2 data from safety sentinel cohort (aggregate of ~25 children) in BEACH301, including new 5th dose level, now expected end of Q1 2027 - - Appointed Jonathan Day as EVP, Clinical Development to advance skeletal dysplasia strategy - - Cash, cash equivalents and marketable securities of $353.9 million at Q2 2026; runway…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TYRA.
U.S. House Trading
No House trades found for TYRA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.